Lead Product(s) : EV102
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Discovery
Sponsor : Akos Biosciences
Deal Size : $61.0 million
Deal Type : Licensing Agreement
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
Details : Under the terms of the licensing agreement, Aries will gain the rights to Enveric’s patented topical product EV102 for the clinical development of radiation dermatitis treatment.
Product Name : EV102
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 15, 2024
Lead Product(s) : EV102
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Discovery
Sponsor : Akos Biosciences
Deal Size : $61.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Discovery
Sponsor : Department of Defense
Deal Size : $3.0 million
Deal Type : Funding
Details : Under the DoD award, EuMentis will conduct preclinical TBI studies in validated large animal model in collaboration with Dr. Todd Killbaugh at the Children’s Hospital of Philadelphia and plans to advance its lead NMDA receptor antagonist candidate for ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 02, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Discovery
Sponsor : Department of Defense
Deal Size : $3.0 million
Deal Type : Funding
Lead Product(s) : KCC2
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Discovery
Sponsor : Kerry Murphy
Deal Size : Undisclosed
Deal Type : Financing
Details : The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.
Product Name : KCC2
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 28, 2020
Lead Product(s) : KCC2
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Discovery
Sponsor : Kerry Murphy
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Discovery
Sponsor : Distributed Bio
Deal Size : Undisclosed
Deal Type : Partnership
Distributed Bio Partners With Mediar Therapeutics, Inc.
Details : Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Discovery
Sponsor : Distributed Bio
Deal Size : Undisclosed
Deal Type : Partnership